ClinVar Miner

Submissions for variant NM_000702.4(ATP1A2):c.1091C>T (p.Thr364Met)

dbSNP: rs1553244881
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
CeGaT Center for Human Genetics Tuebingen RCV001092181 SCV001248567 pathogenic not provided 2022-04-01 criteria provided, single submitter clinical testing ATP1A2: PM6:Strong, PM1, PM2, PS4:Moderate, PP3, PP4
Athena Diagnostics Inc RCV001092181 SCV001476161 pathogenic not provided 2019-12-31 criteria provided, single submitter clinical testing Not found in the total gnomAD dataset, and the data is high quality. Found in at least one patient with expected phenotype for this gene. Predicted to have a damaging effect on the protein. One other pathogenic or likely pathogenic variant affects the same amino acid. One de novo case with parental identity confirmed and one de novo case with parental identity not confirmed.
Ambry Genetics RCV002444756 SCV002734291 likely pathogenic Inborn genetic diseases 2019-04-04 criteria provided, single submitter clinical testing The p.T364M variant (also known as c.1091C>T), located in coding exon 9 of the ATP1A2 gene, results from a C to T substitution at nucleotide position 1091. The threonine at codon 364 is replaced by methionine, an amino acid with similar properties. This variant was identified in 2 individuals with hemiplegic migraines, including a de novo case (Toldo I et al. Cephalalgia, 2011 Apr;31:751-6; Martínez E et al. Case Rep Neurol Med, 2016 Oct;2016:3464285). This variant also occurred de novo in a child with autism, abnormal hair and nail growth, episodes of arm movement and loss of awareness, and one episode of right sided weakness and non-fluent aphasia with left cranial headache (Benke PJ et al. Pediatr. Neurol., 2018 02;79:61-64). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic.
Baylor Genetics RCV003147390 SCV003835961 pathogenic Migraine, familial hemiplegic, 2 2022-11-13 criteria provided, single submitter clinical testing
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ RCV001092181 SCV001955657 uncertain significance not provided no assertion criteria provided clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center RCV001092181 SCV001975408 uncertain significance not provided no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.